Showing 313-336 of 756 published briefings.
NZX results archive
NZX company results and financial reports.
Read what changed in the latest company results, compare equivalent periods, and open issuer-labelled annual reports and other source documents where available.
Revenue up 15.7% but gross margin improvement masked by widening losses
Strong subscription growth and an 800bps gross margin expansion to 67% haven't stopped the pre-tax loss deepening to NZ$7.1m as operating costs
Published 18 May 2026
Read briefingCash burn accelerated 71.8% as NPAT loss widened 40.6%
The pre-revenue gold explorer added a processing plant, leaving NZ$1.2m cash against a half-year free cash burn of NZ$1.4m.
Published 23 April 2026
Read briefingPBT up 17.1% but cash quality leans on capex cut and working capital release
Earnings returned to growth on a -1.9% revenue base, but FCF of NZ$6.1m reflects capex falling 92% and an unusual working capital release.
Published 22 April 2026
Read briefingPortfolio return of 10.4% drove Kingfish to NZ$42.8m interim profit
Recurring investment income held flat at NZ$5.5m, leaving distributions only 48.8% income-covered despite the headline swing.
Published 22 April 2026
Read briefingHY25 interim NPAT $33.0m as revaluation turns positive; NTA edges to $1.46
Period-shape mismatch against FY24 distorts growth rates; gearing rose to 37.2% with AFFO payout at 105%.
Published 22 April 2026
Read briefingCyclone rebound lifts PBT 68.8% as pre-lease FCF reaches NZ$40.8m
Revenue rose 19.4% on post-Cyclone Gabrielle volume recovery, but an elevated 33.5% effective tax rate compresses the NPAT read versus PBT.
Published 23 April 2026
Read briefingRevenue +33.3% but NPAT swung -118.1% against HY24 one-off gain
Underlying proportionate EBITDAF rose 7%, while operating cash conversion fell from 41.6% to 18.4% as capex stepped up 25.9%.
Published 22 April 2026
Read briefingGMT operating earnings up 10.6% as valuation drag reverses to $45.5m profit
Underlying rental growth of 7.3% and new completions drove revenue 34.7% higher, but NTA per unit fell 12.7% and borrowings rose $108.6m, tightening
Published 22 April 2026
Read briefingRevenue +8.4% but NPAT -8.0% as costs and debtors absorbed growth
EBITDA rose 6.4% but PBT fell 7.8%, debtors outpaced revenue by nearly 2x, and net debt swung to $88.4m from net cash.
Published 22 April 2026
Read briefingDividend cover rebuilt to 131% as portfolio return rebounded to 11.9%
Revenue return rose 39.9% and refilled the £29.9m revenue reserve, but the portfolio still lagged its Asia Pacific high-yield benchmark by 1.1pp.
Published 22 April 2026
Read briefingPeriod mismatch overshadows HY25 turn to positive EBITDAF and FCF
The supplied -39.7% revenue change compares half-year results to a full year, masking a positive EBITDAF turn and NZ$1.3m of free cash flow.
Published 23 April 2026
Read briefingNet debt swung to $20.1m as cash conversion collapsed to 19.8%
Operating cash fell 70.5% to $6.0m on essentially flat EBITDA, turning free cash flow negative and pushing leverage off a near-zero base.
Published 21 April 2026
Read briefingPBT rose 14.8% but unprecedented 33.8% tax rate held NPAT to 7.8%
Operating performance ran ahead of headline NPAT, yet the dominant Australia segment posted lower profit despite 14% revenue growth.
Published 21 April 2026
Read briefingContinuing PBT halved as all three retail segments compressed
A $60.3m Torpedo7 exit pushed group NPAT to a $54.2m loss, while capex cut to a third propped up free cash flow.
Published 23 April 2026
Read briefingContinuing NPAT fell 6%; total NPAT down 28% on discontinued operation
Strong $1.6b free cash flow funded a 15c special dividend on top of the 40c ordinary payout for FY24.
Published 22 April 2026
Read briefingPBT swung to a $46.7m loss as revenue fell 11.2%
Operating cash held at $144.7m, but the apparent cash-conversion uplift reflects EBITDA collapse rather than improved working-capital quality.
Published 21 April 2026
Read briefingNPAT fell 43% but pro-forma EBITDA rose to $13.5m on biological-asset swing
A $7.7m non-cash biological-asset/inventory swing pulled GAAP earnings down even as volumes, revenue and the company's guided pro-forma measure
Published 23 April 2026
Read briefingGross margin compressed 264bps and pre-lease FCF fell to $3.0m
Operating profit declined 13.6% as capex jumped 4.5x to $35.0m and a 41.3% effective tax rate widened the NPAT decline.
Published 21 April 2026
Read briefingRevenue up 2.4% but PBT collapsed 101% as H2 swung to a NZD 15.9m loss
Operating cash halved and the group flipped from net cash to NZD 38.7m net debt, with no final dividend declared for FY24.
Published 22 April 2026
Read briefingNPAT surged 134.0% but AFFO cash earnings rose only 26.8%
Acquisition-funded growth lifted NPAT 134.0% and revenue 60.2%, yet NTA per share fell 4.9% and the dividend was cut 28.1%.
Published 21 August 2026
Read briefingMOVE FY24: second-half EBITDA turned negative as PBT loss widened to $45.3m
Revenue fell 14.5% and reported EBITDA collapsed 83% to $7.9m, with equity down 64% to $27.2m and gross borrowings now all current.
Published 23 April 2026
Read briefingPBT fell 22.0% on near-flat revenue as impairment charges bit hard
Revenue growth of just 0.2% left no buffer when provisions surged, driving a 22.0% PBT decline and compressing ROE to 6.0% from 9.3%.
Published 22 April 2026
Read briefingOperating cash outflow widened to $27.3m on $7.9m inventory build
FY24 NPAT of $4.6m sits against an insurance-boosted FY23 base, inventory days extended to 133, and cash fell $7.7m to $31.6m.
Published 22 April 2026
Read briefingPre-lease FCF collapsed to NZ$19m as capex rose 31% and OCF halved
NPAT stepped down off the FY23 reopening peak, but the cash squeeze leaves an 81.4% NPAT payout uncovered by free cash flow.
Published 22 April 2026
Read briefingGet reporting-season briefings
Get full NZX result briefings by email as new coverage is published.